How Is Medical Device Product Classification Determined for India Registration?

To determine how a medical device should be classified for registration in India, a manufacturer should first confirm the target country, the product's risk level, the applicable regulatory pathway and the existing documentation base — and only then assess technical file, quality management system, labelling and instructions for use, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission, so that an unclear classification, an incomplete dossier or an undefined authorisation arrangement does not unnecessarily extend the project timeline. For Chinese medical device manufacturers, the most reliable approach is to complete the product classification and gap assessment first, and then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Published: 2026-07-15 13:02  |  Updated: 2026-07-15 13:02

This FAQ addresses the questions companies most need to resolve first in international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Key Summary

On the question of how product classification for India registration should be determined, companies should first confirm the target country, the product risk level, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid project delays caused by unclear classification, incomplete documentation or undefined authorisation arrangements.

For Chinese medical device manufacturers, the more prudent approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market typically affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of "which documents must be submitted", deficiency letters and rework are more likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends placing this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation across markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on how product classification for India registration is determined are usually not looking for a conceptual explanation. What they need to establish is whether existing documentation can support a submission in the target market, whether a local agent or authorised representative is required, why timelines become extended, and which issues may affect the launch plan. Behind this question are typically product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process question for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then carry out localisation adjustments in line with each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, method of body contact, duration of use, whether the device is sterile, whether it is active, and whether it contains software or has IVD characteristics, and then determine the risk level and submission pathway. If the pathway is assessed incorrectly, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these points are handled only vaguely in a commercial contract, market control can easily be affected later.

Documents and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Instructions for use claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must all support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

• Treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Translating NMPA documentation directly and submitting it without reorganising the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling cover insufficient scope.
• Selecting a local agent purely on the basis of a sales relationship, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failure to plan for multi-country documentation reuse in advance, resulting in duplicated preparation for each country and higher cost and longer timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Establish a target country gap assessment table identifying what must be retested, translated, notarised or supported by additional declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies treat target market registration not as a one-off document submission but as an overseas market access programme to be managed. For companies preparing to enter multiple countries, establishing one clear core technical file and evidence matrix first, and then converting it according to national requirements, is usually faster, more stable and more favourable for subsequent changes and renewals than filling documentation gaps country by country on an ad hoc basis.

From a project management perspective, three matters should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the boundaries of regulatory responsibility of local partners. If these three items are unclear, the project may still encounter repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it generally cannot be submitted as is. Companies need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target markets and product list. The earlier the gap assessment is completed, the easier it is to schedule retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, certificate renewal and post-market incident handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, model and specification data, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management assess whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, identifying which documents can serve as core evidence and which must be reissued or supplemented in line with national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must be maintained at consistent versions.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarisation, testing and deficiency response status.
• Schedule post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, model and specification data or instructions for use version are inconsistent with the test reports, additional clarification may be requested even where a large volume of documentation has been prepared.

Before submission, companies should prepare an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version and quality system certificate item by item. This step appears basic, but it can materially reduce the likelihood of deficiency letters, particularly for projects involving simultaneous submissions in several GHWP member states or for multiple product families.

Localisation Conversion and Agent Responsibilities

Target market registration projects usually involve arrangements with a local agent, authorised representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate, isolated set of documentation.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean the compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest significant effort at the certification stage but neglect post-market maintenance; when a manufacturing address change, model extension, instructions for use update or agent replacement occurs, the certificate and commercial sales can then become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater efficiency in registering in a single country; more importantly, it enables companies to build a replicable overseas compliance capability and reduce the cost of starting documentation preparation from zero every time they enter a new market.

Continue Reading

Previous: How Should Documentation Be Prepared for Medical Device Registration in India?

Next: How Should the Technical File for Medical Device Registration in India Be Organised?

Recommended reading

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Are Authorised Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Do Medical Device Registration Timelines in Brazil Become Extended?
• What Are the Common Reasons for Deficiency Letters in Brazilian Medical Device Registration?
• How Should Post-Market Surveillance Be Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Filed for Medical Device Registration in Brazil?

Back to the FAQ Centre  |  News  |  Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Sourcing principle: priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Applicability boundaries: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice. This content has been compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.